Diverse pharmacovigilance jurisdiction—The right way for global drug safety?

被引：0
作者：
Petra Zatovkaňuková
Jiří Slíva
机构：
[1] Charles University,Department of Pharmacology, Third Faculty of Medicine
来源：
European Journal of Clinical Pharmacology | 2024年 / 80卷
关键词：
Pharmacovigilance; Adverse drug reaction reporting; Czech Republic; Canada; Japan; United Kingdom; China; United States; Legislation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：305 / 315
页数：10
相关论文
共 19 条
  • [1] Routledge PA(2004)Adverse drug reactions in elderly patients Br J Clin Pharmacol 57 121-126
  • [2] O’Mahony MS(2007)Which drugs cause preventable admissions to hospital? A systematic review Br J Clin Pharmacol 63 136-147
  • [3] Woodhouse KW(2018)Pharmacovigilance in China: development and challenges Int J Clin Pharm 40 823-831
  • [4] Howard RL(2022)Factors that lead to stagnation in direct patient reporting of adverse drug reactions: an opinion survey of the general public and physicians in Japan Ther Innov Regul Sci 56 616-624
  • [5] Avery AJ(2019)Establishment of the MID-NET® medical information database network as a reliable and valuable database for drug safety assessments in Japan Pharmacoepidemiol Drug Saf 28 1395-1404
  • [6] Slavenburg S(2006)Adverse drug reactions result in 250 000 UK admissions a year BMJ 332 1109-undefined
  • [7] Zhao Y(2022)A standardized dataset of a spontaneous adverse event reporting system Healthcare (Basel) 10 420-undefined
  • [8] Wang T(undefined)undefined undefined undefined undefined-undefined
  • [9] Li G(undefined)undefined undefined undefined undefined-undefined
  • [10] Sun S(undefined)undefined undefined undefined undefined-undefined
12